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A B S T R A C T   
Stargardt disease (STGD1) is the most common inherited retinal dystrophy and ABCA4 c.546-–10 T>C is the most commonly reported splice mutation. Here, we 
generated and characterized two induced pluripotent stem cell (iPSC) lines from a STGD1 patient with compound heterozygous mutations in ABCA4 (c.[5461-10 T >
C;5603A > T];[4163 T > C;455G > A]). Episomal vectors containing OCT4, SOX2, KLF4, L-MYC, LIN28 and mp53DD were employed to conduct the reprogramming 
of patient-derived fibroblasts. Both lines had a normal karyotype, displayed iPSC morphology, expressed pluripotency markers and showed trilineage differentiation 
potential. These lines can provide a powerful platform for further investigating the pathophysiological consequences of mutations in ABCA4.   
1. Resource Table:  




Alternative name(s) of 
stem cell lines 
1629ips9 (LEIi017-A) 
1629ips11 (LEIi017-B) 
Institution Lions Eye Institute 
Contact information of 
distributor 
Samuel McLenachan: smclenachan@lei.org.au 
Fred K. Chen: fredchen@lei.org.au 
Type of cell lines iPSC 
Origin Human 
Additional origin info 
required 
for human ESC or iPSC 
Age: 16 
Sex: Female 
Ethnicity if known: Caucasian 
Cell Source Dermal fibroblasts 
Clonality Clonal 
Associated disease Stargardt disease 
Gene/locus ABCA4/1p22.1 
Date archived/stock date Both lines 24/06/2020 
Cell line repository/bank 




Ethical approval University of Western Australia Human Research Ethics 
Committee RA/4/1/7916  
2. Resource utility 
Autosomal recessive Stargardt disease is the most common form of 
juvenile-onset macular degeneration and is caused by mutations in the 
ABCA4 gene (Allikmets et al., 1997). The LEIi017-A and LEIi017-B lines 
generated from a patient carrying compound heterozygous ABCA4 
mutations will provide a powerful resource for investigating the effects 
of ABCA4 mutations. 
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3. Resource details 
Stargardt disease (STGD1, OMIM:248200) is the most common 
retinal dystrophy featured by progressive central vision loss (Huang 
et al., 2020). Mutations in the ATP-binding cassette transporter gene 
(ABCA4) have been associated with heterogeneous retinal phenotypes 
ranging in severity from early-onset cone-rod dystrophy to late-onset 
macular dystrophy (Allikmets et al., 1997; Maugeri et al., 2000; Crem-
ers et al., 1998). Here, we report the generation and characterization of 
two iPSC lines from a patient diagnosed with STGD1 caused by com-
pound heterozygous mutations in ABCA4 (c.[5461-10 T > C;5603A >
T]; [4163 T > C;455G > A]). 
The female patient presented with reduced vision at the age of 6 
years without retinal lesions. Electroretinography at age 9 demonstrated 
an electronegative waveform. Stargardt disease was suspected at age 15 
when flecks were first noted. By age 16, her visual acuity had dropped to 
6/120 in both eyes. Genetic analysis using the Stargardt/Macular dys-
trophy panel (version 3; 10 genes) identified four mutations in ABCA4 
(NM_000350.2). Phase analysis was performed by targeted Sanger 
sequencing of parental DNA, demonstrating the maternal complex allele 
carries c.[5461–10 T > C;5603A > T] and the paternal complex allele 
carries c.[4163 T > C;455G > A]. Dermal fibroblasts were sourced and 
cultured from the patient (Huang et al., 2020). Reprogramming of fi-
broblasts into iPSC was conducted using episomal plasmids encoding 
OCT4; SOX2, KLF4, L-MYC, LIN28 and mp53DD. Two clonal iPSC lines 
(LEIi017-A and LEIi017-B) were established for further characterization 
(Table 1). Both LEIi017-A and LEIi017-B displayed morphology typical 
of pluripotent stem cell colonies (Fig. 1A). The expression of pluripo-
tency markers (OCT4, NANOG, SOX2 and KLF4) was demonstrated by 
immunocytochemistry at passage 33, and the cell nuclei were stained 
with DAPI (Fig. 1A). All ABCA4 mutations detected in the patient were 
confirmed in both LEIi017 iPSC lines by Sanger sequencing (Fig. 1B). 
Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
demonstrated OCT4, NANOG, SOX2, KLF4 and MYC mRNA was 
expressed comparably in LEIi017-A and LEIi017-B (passage 11), and in a 
control human iPSC line (HuiPSC, Fig. 1C). The capacity of LEIi017-A 
and LEIi017-B to differentiate into three germ layers was confirmed 
by the expression of markers of ectoderm (PAX6, OTX1), mesoderm 
(TBXT, NKX2.5) and endoderm (AFP, SOX17) lineages in differentiating 
embryoid body (EB) cultures by RT-qPCR. After 14-day spontaneous 
differentiation, EBs derived from LEIi017-A (passage 35) and LEIi017-B 
(passage 34) increased expression of ectoderm, mesoderm and endo-
derm markers, compared with undifferentiated iPSC (Fig. 1D). Digital 
karyotyping using the Infinium Human CoreExome-24 Beadchip SNP 
array (Illumina, San Diego, California, United States) with genome-wide 
copy number variation (CNV) profiling demonstrated both lines were 
female and had a normal diploid karyotype (46,XX). Analysis of the B 
allele frequencies and LogR ratios of ≈500,000 single nucleotide poly-
morphisms located across the genome demonstrated an absence of 
reprogramming-induced chromosomal rearrangements in LEIi017-A 
and LEIi017-B (passage 12 for both, Fig. 1E). Genotyping of 16 micro-
satellite markers confirmed both iPSC lines were derived from the pa-
tient’s fibroblasts (data not shown). LEIi017-A (passage 12) and 
LEIi017-B (passage 12) were negative for reprogramming episomes 
and mycoplasma (Fig. 1F). The 130 bp GAPDH internal control product 
was amplified from LEIi017-A and LEIi017-B (Fig. 1F). 
4. Materials and methods 
Ethics: This work was approved by the University of Western 
Australia Human Research Ethics Committee (RA/4/1/7916). Written 
consent was obtained from the patient and all procedures complied with 
requirements of the National Health & Medical Research Council of 
Australia (National Statement on Ethical Conduct in Human Research 
(2007, updated 2018) and the Declaration of Helsinki. 
Cell culture: Fibroblasts were cultured in DMEM (11995065, Gibco) 
supplemented with 10% fetal bovine serum (FBS, 26140079, Gibco) and 
1 × Antibiotic-Antimycotic (15240062, Gibco). Human iPSC lines were 
cultured on Geltrex-coated (A1413202, Gibco) plates in TeSR-E8 me-
dium (05990, StemCell Technologies) and passaged using TrypLE Ex-
press Enzyme (12604021, Gibco) every 4–5 days using a split ratio of 
1:3–1:6. Both fibroblasts and iPSC cultures were maintained at 37 ◦C 
with 5% CO2. 
Reprogramming: Fibroblasts were reprogrammed using the Epi5TM 
Episomal iPSC Reprogramming Kit (A15960, Invitrogen). Fibroblast 
cells (1 × 105) were electroporated using the Invitrogen NEON elec-
troporation system (three 10 ms pulses at 1650 V in a 10 μl tip). iPSC 
colonies were picked for clonal expansion on day 28. 
Trilineage differentiation: EB differentiation was performed by 
seeding iPSC clusters into 6-well suspension plates containing mTesR1 
medium (85850, StemCell Technologies) and 10 µM Y27632 (ab120129, 
Abcam). On day 3, medium was changed to DMEM/F12 (11320033, 
Gibco) supplemented with 20% knockout serum replacement (KSR, 
10828–028, Gibco), Antibiotic–Antimycotic and MEM-non essential 
amino acids (MEM-NEAA, 11140050,Gibco). Half medium changes 
were performed daily and EB RNA was harvested at day 14. 
RNA analysis: RNA extraction was performed using MagMAX TM- 
96 Total RNA Isolation kit (AM1830, Invitrogen). RT-qPCR was per-
formed with RT2 SYBR Green qPCR Mastermix (330503, Qiagen) on the 
BioRad CFX Connect Real-Time System (45 cycles, 95 ◦C for 30 s, 60 ◦C 
for 60 s). Gene expression was quantified using the ΔCT method, 
normalized to GAPDH expression. Primers used are listed in Table 2. 
Table 1 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography Bright field Normal Fig. 1, 
panels A 
Phenotype Qualitative analysis: 
Immunocytochemistry 
















Genotype Karyotype (the Infinium 
HumanCytoSNP-12 
Beadchip SNP array) and 
resolution 
46,XX 
Resolution 500 kb 
Fig. 1, 
panels E 
Identity  STR analysis 
performed  







Sequencing ABCA4 c. 
[5461–10 T >
C;5603A > T]; 































Blood group genotyping N/A N/A 
HLA tissue typing N/A N/A  
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Immunocytochemistry analysis: Patient iPSCs were fixed with 4% 
paraformaldehyde for 15 min at 37◦C, washed with PBS and incubated 
with blocking buffer (5% normal goat serum in PBS containing 0.3% 
Triton X100) for 1 h at room temperature, followed by incubation with 
primary antibodies at 4◦C overnight. Negative controls omitting primary 
antibodies were included. Secondary antibodies and DAPI (1 µg/mL) 
were applied for 1 h at room temperature. Antibodies are listed in 
Table 2. 
Digital karyotyping and microsatellite analysis: Karyotyping was 
performed on LEIi017-A and LEIi017-B by the Australian Genome 
Research Facility (AGRF, Perth, Western Australia), using the Infinium 
Human CoreExome-24 Beadchip SNP array (Illumina, United States). 
CNV analysis was performed using GenomeStudio 2.0 software with the 
cnvPartition 2.0 plugin (Illumina). Microsatellite analysis was per-
formed by AGRF using the Promega Powerplex 16H system (Promega, 
United States). 
Fig. 1. Characterization of LEIi017-A and LEIi017-B iPSC. (A) 
LEIi017-A and LEIi017-B iPSC colonies showed typical pluripotent stem 
cell morphology (brightfield images) and were positive for OCT4, 
NANOG, SOX2 and KLF4 immunostaining (red signal, immunofluores-
cence images). Counterstaining with DAPI (blue signal) demonstrated 
nuclear localization of each marker (merged fluorescence images). 
Negative controls with primary antibodies omitted (2o Ab only) showed 
no background staining. (B) Sanger sequencing chromatograms 
confirmed the presence of the c.[5461-10T>C;5603A>T] and c. 
[4163T>C;455G>A] complex alleles in LEIi017-A and LEIi017-B. (C) 
Quantitative PCR analysis demonstrated similar levels of OCT4, 
NANOG, SOX2, KLF4 and C-MYC mRNA expression in LEIi017-A, 
LEIi017-B and a commercial control iPSC line (HUiPS P28). (D) Quan-
titative PCR analysis demonstrated upregulation of ectoderm (PAX6, 
OTX1), mesoderm (TBXT, NKX2.5) and endoderm (AFP, SOX17) 
markers and downregulation of OCT4 in embryoid bodies (EB) derived 
from LEIi017-A (upper panel) and LEIi017-B (lower panel), compared 
with undifferentiated iPSC. (E) LogR and B allele frequency (BAF) 
scatter plots of » 500,000 human genomic SNPs demonstrated a normal 
46,XX karyotype in both LEIi017-A and LEIi017-B. (F) PCR analysis 
demonstrated LEIi017-A and LEIi017-B were negative for reprogram-
ming episomes (544bp and 666bp) and mycoplasma DNA (504bp) and 
positive for GAPDH (130bp) at passage 12. Positive controls (+) showed 
amplification of the expected bands. No bands were amplified in 
negative controls without template DNA (-).   
D. Huang et al.                                                                                                                                                                                                                                  
Stem Cell Research 54 (2021) 102448
4
DNA Analysis: Genomic DNA was extracted using FlexiGene DNA 
kit (51206, Qiagen). PCR for Sanger sequencing was performed on a 
GeneTouch Thermal Cycler (35 cycles, 94 ◦C for 30 s, 60 ◦C for 60 s, 
72 ◦C for 2mins). Mycoplasma testing by PCR was performed using the 
Mycoplasma Testing Kit (#091, Media and Monoclonal Laboratories, 
Harry Perkins Institute of Medical Research, Fig. 1F). PCR screening for 
reprogramming episomes was performed using primers listed in Table 2. 
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Table 2 
Reagents details.   
Antibodies used for immunocytochemistry  





























1:250 Invitrogen A11035 AB_2534093   
Primers  
Target Size of 
band 
























OCT4 105 bp CCTGAAGCAGAAGAGGATCACC/ 
AAAGCGGCAGATGGTCGTTTGG  
NANOG 114 bp CTCCAACATCCTGAACCTCAGC/ 
CGTCACACCATTGCTATTCTTCG  
SOX2 134 bp GCTACAGCATGATGCAGGACCA/ 
TCTGCGAGCTGGTCATGGAGTT  
KLF4 110 bp CATCTCAAGGCACACCTGCGAA/ 
TCGGTCGCATTTTTGGCACTGG  





PAX6 130 bp CTGAGGAATCAGAGAAGACAGGC/ 
ATGGAGCCAGATGTGAAGGAGG  
OTX1 159 bp CTACCCTGACATCTTCATGCGG/ 
GGAGAGGACTTCTTCTTGGCTG  
TBXT 152 bp CCTTCAGCAAAGTCAAGCTCACC/ 
TGAACTGGGTCTCAGGGAAGCA  
NKX2.5 146 bp AAGTGTGCGTCTGCCTTTCCCG/ 
TTGTCCGCCTCTGTCTTCTCCA  
AFP 96 bp TGAGCACTGTTGCAGAGGAG/ 
TTGTTTGACAGAGTGTCTTGTTGA  











ABCA4 765 bp CCTTGAGGCACTGCTTGTAAG/ 
GGTCAGGAGGAAGTACACCAC  
ABCA4 585 bp CCATCCAGCCCTGGCTAACT/ 
GGTCACCAGGATGTGTACAGC  
ABCA4 442 bp TGAAGTCTGGCTGAACACTG/ 
CTTCTAAGCAGCATGTGACC  
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